Who are Arcus Biosciences, Inc.'s main suppliers?

Arcus Biosciences, Inc. (RCUS) key suppliers include: TAIHO, WUXI-BIOLOGICS, Celldex Therapeutics, Inc., Celldex Therapeutics, Inc., Innate Pharma S.A. and 5 more. View the full supplier network at chainsifter.com/chain/RCUS.

Who are Arcus Biosciences, Inc.'s major customers?

Arcus Biosciences, Inc. (RCUS) key customers include: GILEAD, TAIHO, AstraZeneca PLC, AstraZeneca PLC, Celldex Therapeutics, Inc. and 14 more. View the full customer network at chainsifter.com/chain/RCUS.

What sector is Arcus Biosciences, Inc. in?

Arcus Biosciences, Inc. (RCUS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

RCUS Supply Chain: Arcus Biosciences, Inc. Supplier List & 31 Relationships

10Suppliers

19Customers

2Debt Items

20Related Chains

Arcus Biosciences, Inc. Suppliers

Ticker	Name	Confidence	Evidence
TAIHO	TAIHO	90%	The Company has full rights to casdatifan and the casdatifan development program, other than those rights licensed to Taiho in Japan and certain other Asian territories (not including China)
WUXI-BIOLOGICS	WUXI-BIOLOGICS	90%	For example, WuXi Biologics, located in China, is currently our sole manufacturer of zimberelimab and domvanalimab.
CLDX	Celldex Therapeutics, Inc.	72%	Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers …
CLDX	Celldex Therapeutics, Inc.	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…
IPHA	Innate Pharma S.A.	72%	Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers …
IPHA	Innate Pharma S.A.	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers …
REGN	Regeneron Pharmaceuticals, Inc.	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers…
SNYNF	Sanofi	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…

Arcus Biosciences, Inc. Customers

Ticker	Name	Confidence	Evidence
GILEAD	GILEAD	92%	Revenues from Gilead accounted for 88 % and 100 % of Total revenues for the three months ended March 31, 2026 and 2025, respectively.
TAIHO	TAIHO	90%	License and development services revenue consists of amounts recognized from the portions of the nonrefundable upfront payments received from Gilead and Taiho
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from RCUS graph: nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue …
AZN	AstraZeneca PLC	72%	nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra…
CLDX	Celldex Therapeutics, Inc.	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…
CLDX	Celldex Therapeutics, Inc.	72%	Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from RCUS graph: ny of our investigational products …
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from GILD g…
GILD	Gilead Sciences, Inc.	72%	hase Agreement Amendment; and $ million deferred revenue remaining from the First Gilead Collaboration Agreement Amendment effective December 2021. We determined the entire $ million to be the alloca…
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from RCUS graph: non-public information and for comp…
HTGC	Hercules Capital, Inc.	72%	non-public information and for complying with our disclosure obligations under the Regulation FD. Such disclosures will be included on the company’s website under the heading "Investors & Media." Acc…
IPHA	Innate Pharma S.A.	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…
IPHA	Innate Pharma S.A.	72%	Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from IPHA g…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from RCUS graph: nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue …
MRK	Merck & Co., Inc.	72%	nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra…
REGN	Regeneron Pharmaceuticals, Inc.	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from REGN g…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RCUS graph: Reciprocal relationship from SNYN…
SNYNF	Sanofi	72%	ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufacturing infrastructure for their optioned…
BEIGENE-LTD	BEIGENE-LTD	62%	nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along with Gilead’s internal manufacturing infra…

Arcus Biosciences, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
RCUS-DEBT	Debt stack $113.0M	90%	Market cache reports total debt of $113.0M.
RCUS-DEBT-12082	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2018-12-31.

Arcus Biosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Arcus Biosciences, Inc..

Arcus Biosciences, Inc. Ownership

Holder	Name	Confidence	Evidence
RCUS-OWNER-GILEAD-SCIENCES-INC	GILEAD SCIENCES, INC.	90%	13F overlay lists GILEAD SCIENCES, INC. as top holder; 213 tracked holders.

Arcus Biosciences, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
CCCC	C4 Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BNBX	BNB Plus Corp.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2

Arcus Biosciences, Inc. Supply Chain